$REGN
REGENERON PHARMACEUTICALS, INC.

2020 Q2 Form 10-Q Financial Statement

#000180422020000022 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $1.952B $1.864B $1.578B
YoY Change 23.72% -3.34% -1.88%
Cost Of Revenue $275.5M $223.9M $145.8M
YoY Change 88.96% 91.04% 59.0%
Gross Profit $1.677B $1.946B $1.432B
YoY Change 17.07% 7.46% -5.57%
Gross Profit Margin 85.89% 104.41% 90.76%
Selling, General & Admin $348.3M $586.8M $294.6M
YoY Change 18.23% 19.44% -19.24%
% of Gross Profit 20.78% 30.16% 20.57%
Research & Development $722.0M $683.1M $885.5M
YoY Change -18.46% 12.67% 67.3%
% of Gross Profit 43.07% 35.11% 61.84%
Depreciation & Amortization $58.80M $54.30M $52.10M
YoY Change 12.86% 26.87% 55.06%
% of Gross Profit 3.51% 2.79% 3.64%
Operating Expenses $1.070B $1.270B $1.180B
YoY Change -9.3% 16.24% 31.99%
Operating Profit $656.4M $675.7M $315.6M
YoY Change 107.98% -5.9% -49.28%
Interest Expense $9.700M $53.20M $8.000M
YoY Change 21.25% -828.77% 15.94%
% of Operating Profit 1.48% 7.87% 2.53%
Other Income/Expense, Net $262.5M $160.9M -$90.90M
YoY Change -388.78% -566.38% -368.14%
Pretax Income $918.9M $889.8M $224.7M
YoY Change 308.95% 31.59% -65.75%
Income Tax $21.60M $97.80M $31.60M
% Of Pretax Income 2.35% 10.99% 14.06%
Net Earnings $897.3M $792.0M $193.1M
YoY Change 364.68% -3.46% -64.98%
Net Earnings / Revenue 45.97% 42.5% 12.24%
Basic Earnings Per Share $8.19 $7.25 $1.77
Diluted Earnings Per Share $7.61 $6.93 $1.68
COMMON SHARES
Basic Shares Outstanding 109.6M shares 109.2M shares
Diluted Shares Outstanding 117.9M shares 114.6M shares

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.144B $3.214B $2.670B
YoY Change 17.75% 14.38% 58.55%
Cash & Equivalents $1.992B $1.618B $1.046B
Short-Term Investments $1.152B $1.597B $1.624B
Other Short-Term Assets $770.0M $788.0M $598.0M
YoY Change 28.76% 37.76% 30.0%
Inventory $1.641B $1.416B $1.317B
Prepaid Expenses
Receivables $1.991B $2.100B $1.920B
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.860B $7.689B $6.651B
YoY Change 18.18% 19.26% 38.13%
LONG-TERM ASSETS
Property, Plant & Equipment $3.031B $2.890B $2.677B
YoY Change 13.26% 12.21% 8.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.658B $3.312B $2.885B
YoY Change -7.87% 83.9% 41.08%
Other Assets $175.5M $144.7M $139.8M
YoY Change 25.54% 13.58% 63.19%
Total Long-Term Assets $6.569B $7.116B $6.523B
YoY Change 0.7% 34.6% 26.97%
TOTAL ASSETS
Total Short-Term Assets $7.860B $7.689B $6.651B
Total Long-Term Assets $6.569B $7.116B $6.523B
Total Assets $14.43B $14.81B $13.17B
YoY Change 9.53% 26.17% 32.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $380.0M $418.1M $244.0M
YoY Change 55.74% 91.61% 41.86%
Accrued Expenses $1.257B $1.087B $877.0M
YoY Change 43.33% 40.8% 30.7%
Deferred Revenue $591.7M
YoY Change 30.76%
Short-Term Debt $1.500B $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.702B $2.097B $1.713B
YoY Change 116.12% 45.31% 28.69%
LONG-TERM LIABILITIES
Long-Term Debt $716.0M $0.00 $711.0M
YoY Change 0.7% -100.0% 0.71%
Other Long-Term Liabilities $457.9M $317.7M $267.9M
YoY Change 70.92% -12.16% 40.99%
Total Long-Term Liabilities $457.9M $317.7M $267.9M
YoY Change 70.92% -12.16% 40.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.702B $2.097B $1.713B
Total Long-Term Liabilities $457.9M $317.7M $267.9M
Total Liabilities $5.371B $3.716B $3.418B
YoY Change 57.16% 24.8% 23.58%
SHAREHOLDERS EQUITY
Retained Earnings $8.902B $7.380B $5.918B
YoY Change 50.41% 40.45% 54.15%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.143B $739.9M $441.8M
YoY Change 1290.43% 86.65% 24.85%
Treasury Stock Shares 15.58M shares 4.860M shares 4.018M shares
Shareholders Equity $9.057B $11.09B $9.756B
YoY Change
Total Liabilities & Shareholders Equity $14.43B $14.81B $13.17B
YoY Change 9.53% 26.17% 32.37%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income $897.3M $792.0M $193.1M
YoY Change 364.68% -3.46% -64.98%
Depreciation, Depletion And Amortization $58.80M $54.30M $52.10M
YoY Change 12.86% 26.87% 55.06%
Cash From Operating Activities $943.4M $787.4M $188.3M
YoY Change 401.01% 8.04% -52.28%
INVESTING ACTIVITIES
Capital Expenditures -$129.9M -$139.0M -$94.60M
YoY Change 37.32% 62.57% -15.54%
Acquisitions
YoY Change
Other Investing Activities $1.583B -$69.70M -$741.4M
YoY Change -313.56% -61.36% 98.77%
Cash From Investing Activities $1.453B -$208.7M -$836.0M
YoY Change -273.85% -21.51% 72.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.613B -345.7M -15.30M
YoY Change 16977.12% 316.51% 36.61%
NET CHANGE
Cash From Operating Activities 943.4M 787.4M 188.3M
Cash From Investing Activities 1.453B -208.7M -836.0M
Cash From Financing Activities -2.613B -345.7M -15.30M
Net Change In Cash -216.0M 233.0M -663.0M
YoY Change -67.42% -38.67% 552.56%
FREE CASH FLOW
Cash From Operating Activities $943.4M $787.4M $188.3M
Capital Expenditures -$129.9M -$139.0M -$94.60M
Free Cash Flow $1.073B $926.4M $282.9M
YoY Change 279.39% 13.77% -44.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-19034
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3444607
dei Entity Address Address Line1
EntityAddressAddressLine1
777 Old Saw Mill River Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Tarrytown
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10591-6707
dei City Area Code
CityAreaCode
914
dei Local Phone Number
LocalPhoneNumber
847-7000
dei Security12b Title
Security12bTitle
Common Stock - par value $.001 per share
dei Trading Symbol
TradingSymbol
REGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1992200000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1617800000 USD
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1152000000.0 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1596500000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1991000000.0 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2100000000.0 USD
CY2020Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
389200000 USD
CY2019Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
260600000 USD
CY2020Q2 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
431100000 USD
CY2019Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
425000000.0 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
1640900000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1415500000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
263800000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
273700000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
7860200000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
7689100000 USD
CY2020Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2587600000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3256800000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3031400000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2890400000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
774000000.0 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
824200000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175500000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144700000 USD
CY2020Q2 us-gaap Assets
Assets
14428700000 USD
CY2019Q4 us-gaap Assets
Assets
14805200000 USD
CY2020Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
380100000 USD
CY2019Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
418100000 USD
CY2020Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1257000000.0 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1211400000 USD
CY2020Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
1500000000.0 USD
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0 USD
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
103800000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
85000000.0 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3702400000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2096600000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
715900000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
713900000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
457900000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
317700000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
5371300000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
3715500000 USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6263000000.0 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4428600000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
8901700000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
7379800000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
35500000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21100000 USD
CY2020Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
15578240 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
4860123 shares
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
6142900000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
739900000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9057400000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11089700000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14428700000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14805200000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1952000000.0 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1577800000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3780200000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2950400000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
722000000.0 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
885500000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1305900000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1371600000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
348300000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
294600000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
715600000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
585700000 USD
CY2020Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
50200000 USD
CY2019Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
63700000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
90600000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
120400000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
1295600000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
1262200000 USD
us-gaap Costs And Expenses
CostsAndExpenses
2423700000 USD
us-gaap Costs And Expenses
CostsAndExpenses
2154800000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
656400000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
315600000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1356500000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
795600000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
272200000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-82900000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
246800000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9100000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
9700000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
8000000.0 USD
us-gaap Interest Expense
InterestExpense
15800000 USD
us-gaap Interest Expense
InterestExpense
15700000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
262500000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-90900000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
231000000.0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24800000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
918900000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
224700000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1587500000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
770800000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21600000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31600000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65600000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
116600000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
897300000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
193100000 USD
us-gaap Net Income Loss
NetIncomeLoss
1521900000 USD
us-gaap Net Income Loss
NetIncomeLoss
654200000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.19
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
13.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.00
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.61
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
13.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.69
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109600000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109100000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117900000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116800000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115000000.0 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
897300000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
193100000 USD
us-gaap Net Income Loss
NetIncomeLoss
1521900000 USD
us-gaap Net Income Loss
NetIncomeLoss
654200000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
44600000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14400000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15800000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30500000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-1400000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-1400000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-2400000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
941900000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
206100000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1536300000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
682300000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11089700000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
817400000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
155100000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
114900000 USD
CY2020Q1 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
14600000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
336000000.0 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000000.0 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
624600000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-30200000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
12133000000.0 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1355500000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
416500000 USD
CY2020Q2 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
10100000 USD
CY2020Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
5071800000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105200000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
897300000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44600000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9057400000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8757300000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
140900000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
10700000 USD
CY2019Q1 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
10500000 USD
CY2019Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
54000000.0 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
114800000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
461100000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
15100000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9444700000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13900000 USD
CY2019Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
29700000 USD
CY2019Q2 regn Stock Issued Distributed During Period Value Employee Benefit Plan
StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan
11700000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
109200000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
193100000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
13000000.0 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
9755900000 USD
us-gaap Net Income Loss
NetIncomeLoss
1521900000 USD
us-gaap Net Income Loss
NetIncomeLoss
654200000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
103100000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
209300000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
213700000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
175800000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-110700000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-118000000.0 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
125300000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
47100000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
247500000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
233400000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
168200000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33800000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33200000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
78900000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
129800000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20900000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
381600000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
40500000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
119500000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
431100000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1641400000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1085300000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1533500000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2189100000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2843700000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
745900000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
300000000.0 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
168900000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1010200000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1612100000 USD
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1500000000.0 USD
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2168000000.0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
155100000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
571600000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5373600000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10000000.0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2277200000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
104600000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
374400000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-422200000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1630300000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1480200000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2004700000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1058000000.0 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1211400000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
85000000.0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
317700000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1577800000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2950400000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
885500000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1371600000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
294600000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
585700000 USD
CY2019Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
63700000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
120400000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
1262200000 USD
us-gaap Costs And Expenses
CostsAndExpenses
2154800000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
129800000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
381600000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. We considered the potential impact of the COVID-19 pandemic on our estimates and assumptions and there was not a material impact to our condensed consolidated financial statements as of and for the three and six months ended June 30, 2020; however, actual results could differ from those estimates and there may be changes to our estimates in future periods.</span></div>
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
897300000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
193100000 USD
us-gaap Net Income Loss
NetIncomeLoss
1521900000 USD
us-gaap Net Income Loss
NetIncomeLoss
654200000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109600000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109100000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117900000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116800000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115000000.0 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.19
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
13.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.00
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.61
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
13.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.69
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2890300000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
44900000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
700000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2934500000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4206300000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28500000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
300000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4234500000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1152000000.0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1596500000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1779600000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
2638000000.0 USD
CY2020Q2 regn Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year5
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
2900000 USD
CY2019Q4 regn Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year5
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYear5
0 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2934500000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4234500000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
274500000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
300000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
274500000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
300000 USD
CY2020Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
28000000.0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
28300000 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2019Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2020Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
228100000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
171300000 USD
CY2019Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-116900000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-74100000 USD
CY2020Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
70600000 USD
CY2019Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
55600000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
306300000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
216300000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
696900000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
727700000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
132000000.0 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
70600000 USD
CY2020Q2 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
505700000 USD
CY2019Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
400900000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
1640900000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1415500000 USD
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.024
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.141
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.041
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.151
CY2020Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
9806805 shares
CY2020Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
5000000000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1992200000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1045500000 USD
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
12500000 USD
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
12500000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2004700000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1058000000.0 USD
CY2020Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
87400000 USD
CY2019Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
133700000 USD
CY2019Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
74700000 USD
CY2018Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
54500000 USD
CY2020Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
132200000 USD
CY2019Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
100000000.0 USD

Files In Submission

Name View Source Status
0001804220-20-000022-index-headers.html Edgar Link pending
0001804220-20-000022-index.html Edgar Link pending
0001804220-20-000022.txt Edgar Link pending
0001804220-20-000022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-20200630.htm Edgar Link pending
regn-20200630.xsd Edgar Link pending
regn-20200630_cal.xml Edgar Link unprocessable
regn-20200630_def.xml Edgar Link unprocessable
regn-20200630_htm.xml Edgar Link completed
regn-20200630_lab.xml Edgar Link unprocessable
regn-20200630_pre.xml Edgar Link unprocessable
regn-ex1021x06302020x1.htm Edgar Link pending
regn-ex103x06302020x10q.htm Edgar Link pending
regn-ex104x06302020x10q.htm Edgar Link pending
regn-ex311x06302020x10q.htm Edgar Link pending
regn-ex312x06302020x10q.htm Edgar Link pending
regn-ex32x06302020x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending